Guidance
12 Sources of evidence considered by the Committee
The diagnostics assessment report was prepared by Warwick Evidence.
-
Waugh, Cummins and Royle et al. Faecal calprotectin testing for differentiating amongst inflammatory and non‑inflammatory bowel diseases: a systematic review and economic evaluation, April 2013
Registered stakeholders
The following organisations accepted the invitation to participate in this assessment as stakeholders. They were invited to attend the scoping workshop and to comment on the diagnostics assessment report and the diagnostics consultation document.
Manufacturers/sponsors:
The technologies under consideration
-
Bühlmann – EK-CAL calprotectin ELISA test
-
Bühlmann – LF-CAL25 Quantum Blue calprotectin test
-
Bühlmann – LF-CHR 25 Quantum Blue calprotectin test
-
Calpro – CALPRO CALPROTECTIN ELISA TEST (ALP) CAL0100
-
Calpro – CALPROLAB CALPROTECTIN ELISA (ALP) CALP0170
-
Eurospital – Calprest
-
Eurospital – CalFast
-
Immundiagnostik – ELISA (K6927)
-
Immundiagnostik – ELISA (K6937)
-
Immundiagnostik – ELISA (K6967)
-
Phadia AB, part of Thermo Fisher Scientific – EliA Calprotectin
-
Preventis – KST11005 CalDetect Calprotectin Rapid test (version 1 – Caldetect)
-
Preventis – CalDetect Calprotectin Rapid test (version 3 – CalScreen)
Professional groups:
-
The British Society of Gastroenterology
-
The Royal College of Nursing
-
The Royal College of Pathologists
-
The Royal College of Physicians
Others:
-
Department of Health
-
Healthcare Improvement Scotland
-
Leeds General Infirmary
-
Birmingham Quality (UK NEQAS)
-
Royal Wolverhampton NHS Trust
-
Epsom & St Helier NHS Trust
-
St George's Hospital and Medical School
-
Sherwood Forest Hospitals NHS Foundation Trust
-
St George's Medical Centre, New Brighton
-
Brighton and Sussex University Hospitals
-
St Mark's Hospital, Harrow
ISBN: 978-1-4731-0326-9